Theratechnologies Inc
TSX:TH

Watchlist Manager
Theratechnologies Inc Logo
Theratechnologies Inc
TSX:TH
Watchlist
Price: 2.6 CAD 0.78% Market Closed
Market Cap: 119.5m CAD
Have any thoughts about
Theratechnologies Inc?
Write Note

Net Margin
Theratechnologies Inc

-3.8%
Current
-41%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-3.8%
=
Net Income
-3.2m
/
Revenue
84.3m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
CA
Theratechnologies Inc
TSX:TH
119.5m CAD
-4%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
316.5B USD
9%
US
Amgen Inc
NASDAQ:AMGN
141.2B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.3B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.2B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-14%
Country CA
Market Cap 119.5m CAD
Net Margin
-4%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 316.5B USD
Net Margin
9%
Country US
Market Cap 141.2B USD
Net Margin
13%
Country US
Market Cap 117.1B USD
Net Margin
0%
Country US
Market Cap 105.3B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.7B AUD
Net Margin
18%
Country US
Market Cap 78.2B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36B EUR
Net Margin
-14%
No Stocks Found

Theratechnologies Inc
Glance View

Market Cap
119.5m CAD
Industry
Biotechnology

Theratechnologies, Inc. is a pharmaceutical company. The company is headquartered in Montreal, Quebec and currently employs 87 full-time employees. The firm has two approved products: EGRIFTA SV in the United States, and Trogarzo in the United States, the European Union and the United Kingdom. EGRIFTA SV (tesamorelin for injection) is developed for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Trogarzo (ibalizumab-uiyk) is developed for HIV treatment. The treatment is infused every two weeks. The company is a new class of antiretrovirals (ARV), and is a long-acting ARV therapy that can lead to an undetectable viral load in combination with other ARVs. The firm markets its prescription products in the United States, Europe and Canada. Its research pipeline is focused on specialized therapies addressing unmet medical needs in HIV, oncology and non-alcoholic steatohepatitis (NASH).

TH Intrinsic Value
6.47 CAD
Undervaluation 60%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-3.8%
=
Net Income
-3.2m
/
Revenue
84.3m
What is the Net Margin of Theratechnologies Inc?

Based on Theratechnologies Inc's most recent financial statements, the company has Net Margin of -3.8%.